Elevance Health beats top-line and bottom-line estimates; raises FY26 outlook
Seeking Alpha ·
Elevance Health press release ( ELV ): Q2 Non-GAAP EPS of $7.45 beats by $1.24 . Revenue of $49.83B (+0.8% Y/Y) beats by $1.2B . FY 2026 diluted EPS guidance raised to at least $20.10; adjusted diluted EPS guidance raised to at least $27.00 (prior
AI 시장 분석
Elevance Health reported a Q2 non-GAAP EPS of $7.45, beating market estimates by $1.24. Revenue rose 0.8% YoY to $49.83 billion, exceeding expectations by $1.2 billion. The company raised its 2026 adjusted EPS guidance to at least $27, signaling robust growth.
상승 영향
- Healthcare — ELV's earnings surprise and raised guidance boost expectations for improved profitability across the health insurance sector. Stable cash flows and enhanced shareholder return policies are increasing investment appeal.
DYAX 전담 분석
Elevance Health's strong performance highlights operational efficiency in the managed care sector. By increasing its forward guidance, the company has demonstrated confidence in sustaining long-term earnings growth despite macro uncertainties.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
529 participants
Related News
- Morgan Stanley Q2 earnings beat fueled by stock trading, investment banking fees
- Canfor to close Prince George pulp mill, citing market oversupply
- Nepra Foods moves closer to Idaho Beverage asset acquisition
- Gilat Satellite secures $20M in SkyEdge orders
- At a glance: stocks gapping down premarket
- Redwire pops on $21.5M follow-on order for U.S. Army drone program